Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA.
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA.
Semin Cancer Biol. 2019 Aug;57:52-58. doi: 10.1016/j.semcancer.2019.06.006. Epub 2019 Jun 8.
In the past half century, our version on cancer, from tumor initiation, growth, to metastasis, is dominated by genetic mutation. The importance of metabolism and epigenetics was not recognized until most recently. Extensive cell proliferation is one of the hallmarks of cancers. To support the energetic and anabolic demands of enhanced proliferation, tumors reprogram the pathways of nutrient procurement and metabolism. In this context, a new link between metabolic alterations and cancer progression has been unraveled over the last decade by the studies conducted in the area of cancer cell metabolism. Cancer cells are known to alter their metabolic profile during the course of tumorigenesis and metastasis thereby exhibiting a tightly regulated program of metabolic plasticity. Noteworthy, certain metabolic alteration are known to occur at the epigenetic level, thus making epigenetics and metabolism highly interwoven in a reciprocal manner. Metabolites that are generated during metabolic pathways, such as in glycolytic cycle and oxidative phosphorylation, serve as cofactors or substrates for the enzymatic reactions that catalyze the epigenetic modifications and transcriptional regulation. Several studies also indicate that the epigenome is sensitive to cellular metabolism. Since many of the metabolic alterations and consequently aberrated epigenetic regulation are common to a wide range of cancer types, they serve as promising targets for anti-cancer therapies. Here we discuss the latest findings in cancer cell metabolism, elucidating the major anabolic, catabolic and energetic demands required for sustaining cancer growth, and the influence of altered metabolism on epigenetics and vice versa. A comprehensive research pertaining to metabolomic profiling and epigenome interactors/mediators in malignant neoplasias is imperative in deciphering the potential targets that can be exploited for the development of robust anti-cancer therapies.
在过去的半个世纪中,我们对癌症的认识——从肿瘤的起始、生长到转移——主要基于基因突变。直到最近,代谢和表观遗传学的重要性才被认识到。广泛的细胞增殖是癌症的标志之一。为了支持增强增殖的能量和合成代谢需求,肿瘤重新编程了营养物质获取和代谢的途径。在这种情况下,过去十年在癌症细胞代谢领域的研究揭示了代谢改变与癌症进展之间的新联系。众所周知,癌细胞在肿瘤发生和转移过程中会改变其代谢特征,从而表现出严格调控的代谢可塑性程序。值得注意的是,某些代谢改变已知发生在表观遗传水平,因此表观遗传学和代谢在相互交织的方式中高度交织。代谢途径中产生的代谢物,如糖酵解循环和氧化磷酸化,作为催化表观遗传修饰和转录调控的酶促反应的辅助因子或底物。几项研究还表明,表观基因组对细胞代谢敏感。由于许多代谢改变和随之而来的异常表观遗传调控在广泛的癌症类型中都很常见,因此它们是癌症治疗的有前途的靶点。在这里,我们讨论了癌症细胞代谢的最新发现,阐明了维持癌症生长所需的主要合成代谢、分解代谢和能量需求,以及代谢改变对表观遗传学的影响,反之亦然。对代谢组学分析和恶性肿瘤中表观基因组相互作用物/调节剂进行全面研究对于破译可以用于开发强大的抗癌疗法的潜在靶点至关重要。